Milacron Holdings Corp (MCRN) Expected to Post Earnings of $0.41 Per Share

Share on StockTwits

Equities analysts forecast that Milacron Holdings Corp (NYSE:MCRN) will report earnings per share of $0.41 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Milacron’s earnings, with estimates ranging from $0.39 to $0.43. Milacron reported earnings per share of $0.44 during the same quarter last year, which suggests a negative year-over-year growth rate of 6.8%. The business is expected to issue its next quarterly earnings results before the market opens on Thursday, October 25th.

On average, analysts expect that Milacron will report full year earnings of $1.73 per share for the current financial year, with EPS estimates ranging from $1.68 to $1.78. For the next year, analysts expect that the company will post earnings of $2.03 per share, with EPS estimates ranging from $1.95 to $2.15. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Milacron.

Milacron (NYSE:MCRN) last issued its quarterly earnings results on Thursday, July 26th. The industrial products company reported $0.48 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.48. The business had revenue of $328.10 million during the quarter, compared to analyst estimates of $321.44 million. Milacron had a net margin of 2.85% and a negative return on equity of 85.21%. The business’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.46 earnings per share.

A number of analysts recently issued reports on MCRN shares. TheStreet upgraded shares of Milacron from a “c+” rating to a “b” rating in a research note on Monday, June 25th. Zacks Investment Research lowered shares of Milacron from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. Robert W. Baird restated a “buy” rating and issued a $27.00 price target on shares of Milacron in a research note on Thursday, July 26th. Finally, ValuEngine lowered shares of Milacron from a “hold” rating to a “sell” rating in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. Milacron has a consensus rating of “Hold” and an average price target of $24.00.

In other Milacron news, Director James Gentilcore sold 35,800 shares of the business’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $21.08, for a total transaction of $754,664.00. Following the completion of the sale, the director now owns 34,765 shares in the company, valued at $732,846.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Bruce A. Chalmers sold 79,725 shares of the business’s stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $20.74, for a total transaction of $1,653,496.50. Following the sale, the insider now owns 228,494 shares of the company’s stock, valued at approximately $4,738,965.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 202,744 shares of company stock valued at $4,209,233. Insiders own 2.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MCRN. Schwab Charles Investment Management Inc. increased its stake in Milacron by 20.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 274,657 shares of the industrial products company’s stock valued at $5,532,000 after purchasing an additional 46,498 shares during the last quarter. Northern Trust Corp increased its stake in Milacron by 19.1% during the first quarter. Northern Trust Corp now owns 730,899 shares of the industrial products company’s stock valued at $14,720,000 after purchasing an additional 117,094 shares during the last quarter. BlackRock Inc. increased its stake in Milacron by 16.4% during the first quarter. BlackRock Inc. now owns 3,989,632 shares of the industrial products company’s stock valued at $80,351,000 after purchasing an additional 563,449 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Milacron by 47.7% during the first quarter. JPMorgan Chase & Co. now owns 54,085 shares of the industrial products company’s stock valued at $1,089,000 after purchasing an additional 17,470 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Milacron by 19.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,230,951 shares of the industrial products company’s stock valued at $24,791,000 after purchasing an additional 196,901 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Shares of NYSE:MCRN opened at $17.72 on Tuesday. The company has a debt-to-equity ratio of -5.73, a current ratio of 2.33 and a quick ratio of 1.35. The firm has a market capitalization of $1.29 billion, a P/E ratio of 10.20, a P/E/G ratio of 1.32 and a beta of 0.75. Milacron has a 12-month low of $15.90 and a 12-month high of $22.62.

Milacron Company Profile

Milacron Holdings Corp. manufactures, distributes, and services engineered and customized systems within the plastic technology and processing industry in the United States and internationally. The company operates through three segments: Advanced Plastic Processing Technologies (APPT), Melt Delivery and Control Systems (MDCS), and Fluid Technologies (Fluids).

Recommended Story: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Milacron (MCRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Milacron (NYSE:MCRN)

Receive News & Ratings for Milacron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milacron and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.